Immunity in malignant brain tumors: Tumor entities, role of immunotherapy, and specific contribution of myeloid cells to the brain tumor microenvironment
- 11 December 2023
- journal article
- review article
- Published by Wiley in European Journal of Immunology
- Vol. 54 (2) , e2250257
Abstract
Malignant brain tumors lack effective treatment, that can improve their poor overall survival achieved with standard of care. Advancement in different cancer treatments has shifted the focus in brain tumor research and clinical trials toward immunotherapy‐based approaches. The investigation of the immune cell landscape revealed a dominance of myeloid cells in the tumor microenvironment. Their exact roles and functions are the subject of ongoing research. Current evidence suggests a complex interplay of tumor cells and myeloid cells with competing functions toward support vs. control of tumor growth.Here, we provide a brief overview of the three most abundant brain tumor entities: meningioma, glioma, and brain metastases. We also describe the field of ongoing immunotherapy trials and their results, including immune checkpoint inhibitors, vaccination studies, oncolytic viral therapy, and CAR‐T cells. Finally, we summarize the phenotypes of microglia, monocyte‐derived macrophages, border‐associated macrophages, neutrophils, and potential novel therapy targets.Keywords
This publication has 96 references indexed in Scilit:
- CSF-1R inhibition alters macrophage polarization and blocks glioma progressionNature Medicine, 2013
- Design and Selection of Toca 511 for Clinical Use: Modified Retroviral Replicating Vector With Improved Stability and Gene ExpressionMolecular Therapy, 2012
- TIE2-expressing monocytes as a diagnostic marker for hepatocellular carcinoma correlates with angiogenesisHepatology, 2012
- Brain metastases: pathobiology and emerging targeted therapiesActa Neuropathologica, 2012
- CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasisNature, 2011
- Stereotactic radiosurgery for WHO grade I meningiomasJournal of Neuro-Oncology, 2010
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaNew England Journal of Medicine, 2010
- FDA Drug Approval Summary: Bevacizumab (Avastin®) as Treatment of Recurrent Glioblastoma MultiformeThe Oncologist, 2009
- Polarization of Tumor-Associated Neutrophil Phenotype by TGF-β: “N1” versus “N2” TANCancer Cell, 2009
- Incidence Proportions of Brain Metastases in Patients Diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance SystemJournal of Clinical Oncology, 2004